Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström.
Publication
, Journal Article
Rhodin, KE; Beasley, G
Published in: Ann Surg Oncol
January 2025
Duke Scholars
Published In
Ann Surg Oncol
DOI
EISSN
1534-4681
Publication Date
January 2025
Volume
32
Issue
1
Start / End Page
505 / 507
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Rhodin, K. E., & Beasley, G. (2025). Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström. Ann Surg Oncol, 32(1), 505–507. https://doi.org/10.1245/s10434-024-16299-1
Rhodin, Kristen E., and Georgia Beasley. “Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström.” Ann Surg Oncol 32, no. 1 (January 2025): 505–7. https://doi.org/10.1245/s10434-024-16299-1.
Rhodin KE, Beasley G. Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström. Ann Surg Oncol. 2025 Jan;32(1):505–7.
Rhodin, Kristen E., and Georgia Beasley. “Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström.” Ann Surg Oncol, vol. 32, no. 1, Jan. 2025, pp. 505–07. Pubmed, doi:10.1245/s10434-024-16299-1.
Rhodin KE, Beasley G. Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström. Ann Surg Oncol. 2025 Jan;32(1):505–507.
Published In
Ann Surg Oncol
DOI
EISSN
1534-4681
Publication Date
January 2025
Volume
32
Issue
1
Start / End Page
505 / 507
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis